期刊文献+

肝硬化门静脉高压症的发病机制及药物治疗现状 被引量:3

The pathogenesis and pharmacotherapy of portal hypertension due to liver cirrhosis
下载PDF
导出
摘要   近年有关门静脉高压症的发病机制及实验研究取得较大进展,各种新药物和治疗方法也随之产生。笔者结合近年相关文献,从门静脉高压症的发病机制、食管静脉曲张等方面对门静脉高压症的药物治疗作一综述。
出处 《中国普通外科杂志》 CAS CSCD 2005年第2期138-141,共4页 China Journal of General Surgery
  • 相关文献

参考文献24

  • 1王继见,高根五.门脉高压症发病机理的研究近况[J].中国普外基础与临床杂志,2000,7(4):275-276. 被引量:12
  • 2Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance [J]. Hepatology,1996,24 (1):233-240.
  • 3Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough [J]. Hepatology, 2002, 35 (2): 478-491.
  • 4Hegab AM, Luketic VA. Bleeding esophageal varices How to treat this dreaded complication of portal hypertension [J]. Postgrad Med, 2001, 109(2):75-76;81-86;89.
  • 5D′Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach [J]. Semin Liver Dis, 1999, 19(4):475-505.
  • 6D′Amico G, Luca A. Natural history. Clinical-haemodynamic correlations.Prediction of the risk of bleeding [J]. Baillieres Clin Gastroenterology, 1997, 11(2):243-256.
  • 7de Franchis R, Primignani M. Natural history of portal hypertensionin patients with cirrhosis [J]. Clin Liver Dis, 2001, 5(3): 645-663.
  • 8de Franchis R. Updating consensus in portal hypertension: report ofthe Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension [J]. J Hepatol,2000,33 (5): 846-852.
  • 9Burroughs AK, Patch DW. Management of variceal haemorrhage in cirrhotic patients [J]. Gut, 2001, 48(5):738-740.
  • 10Stanley AJ, Therapondos G, Helmy A, et al. Acute and chronic haemodynamic and renal effects of carvedilol in patients with cirrhosis[J].J Hepatol,1999,30(3):479-484.

二级参考文献19

  • 114,Hartleb M, Moreau K, Cailmail S, et al. Vascular hyporesponsiveness to endothelin-1 in rats with cirrhosis [J]. Gastroenterology, 1994; 107(4)∶1085
  • 215,Ohlstein EH, Elliott JD, Feuerotein GZ, et al. Endothelin receptors: receptor classification, novel receptor antagonists, and potential therapeutic targets [J]. Med Res Rev, 1996; 16(2)∶365
  • 316,Cahill PA, Ming-Chin Hou, Hendrickson R, et al. Increased expression of endothelin receptor in the vasculature of portal hypertensive rats: role in splanchnic hemodynamics [J]. Hepatology, 1998; 28(2)∶396
  • 417,Gandhi CK, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats [J]. Life Sci,1996;58(1)∶55
  • 518,Rockey NC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver, endothelial dysfunction in portal hypertension [J]. Gastroenterology, 1998; 114(2)∶344
  • 619,Pizcuta P, Pique JM, Fernandez M, et al. Modulation of the hyperdynamic circulation of cirrhosis rats by nitric oxide inhibition [J]. Gastroenterology, 1992; 103(2)∶1909
  • 720,Pilette C, Kirstetter P, Sogni P, et al. Dose-dependent of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats [J]. J Gastroenterol Hepatol, 1996; 11(1)∶1
  • 81,Lopez-Talavera JC, Cadelina G, Olchowski J, et al. Thalidomide inhibits tumor necrosis factor, decreases nitric oxide synthesis, and ameliorate the hyperdynamic circulatory syndrome in portal-hypertensive rats [J]. Hepatology, 1996; 23(6)∶1616
  • 92,Stark ME, Szurszewski JH. Role of nitric oxide in gastrointestenal and hepatic function and disease [J]. Gastroenterology, 1992; 103(6)∶1928
  • 103,Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats [J]. Hepatology, 1992; 15(2)∶323

共引文献11

同被引文献17

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部